I just loved the fact that he stated they wouldn't require require additional financing. With the current cash and Baxters upfront payment and involvement here along with key bulk milestones, it's a no loose situation here. This is huge and bet the Investment/fund managers will prop this to the mid 2's to 3 range. Well done Cell Therapeutics!!!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.